Clinical Trial

Study to Evaluate the Safety and Tolerability of EP0042

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2020-10-05; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2021-02-01
Trial Details
NCT Number NCT04581512
Lead Sponsor Ellipses Pharma
Conditions Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Enrollment 70 participants
Start Date 2020-11-02
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-22